Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 20/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480841 | 0.88 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL23086201 | 0.88 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21456809 | 0.68 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7040606 | 0.68 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17504063 | 0.68 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21456832 | 0.68 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9389496 | 0.67 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17504105 | 0.67 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17504072 | 0.67 | SLC6A3 (0.51) | SLC6A3SLC6A4 | |
| SCHEMBL27825512 | 0.66 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2021-12-09 | — | — | US | disclosed |
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2021-12-09 | — | — | US | disclosed |
| WO-2019197670-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553053-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | Red Bull GmbH (AT) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | TFEB, TAAR1, RABGGTB | SLC6A3 444/4885SLC6A2 135/4885SLC6A4 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.